E. Li

发表

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia

M. Freeman, G. Bakris, B. Pitt, 2015, Kidney international.

Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD.

T. Hostetter, Y. Stasiv, G. Klaerner, 2018, Clinical journal of the American Society of Nephrology : CJASN.

Effects of veverimer on serum bicarbonate and physical function in women with chronic kidney disease and metabolic acidosis: a subgroup analysis from a randomised, controlled trial

N. Tangri, D. Wesson, D. Bushinsky, 2022, BMC Nephrology.

Assessment of the Potential for Veverimer Drug-Drug Interactions

Y. Stasiv, G. Klaerner, Scott M. Tabakman, 2021, Drug Metabolism and Disposition.

Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up

M. Baccarani, H. Kantarjian, J. Cortes, 2015, Cancer.

Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses

M. Baccarani, H. Kantarjian, J. Cortes, 2015, Blood Cancer Journal.

Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension

N. Tangri, Y. Stasiv, G. Klaerner, 2019, The Lancet.

Safety and Efficacy of Veverimer in Acidotic Patients With CKD and Heart Failure

D. Bushinsky, V. Mathur, E. Li, 2021, Kidney international reports.

Effects of Veverimer in Older Adults With CKD and Metabolic Acidosis

N. Tangri, V. Mathur, E. Li, 2021, Kidney medicine.

Factors Associated with Vascular Stiffness: Cross-Sectional Analysis from the Chronic Renal Insufficiency Standards Implementation Study

R. Foley, P. Kalra, R. Middleton, 2009, Nephron Clinical Practice.

Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate

M. Baccarani, H. Kantarjian, J. Cortes, 2015, Leukemia & lymphoma.

Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial

N. Tangri, Y. Stasiv, G. Klaerner, 2019, The Lancet.

Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML)

M. Baccarani, J. Cortes, C. Chuah, 2013 .

Patiromer induced a rapid onset of action and sustained potassium (K+) lowering throughout the dosing period in CKD patients with hyperkalemia

G. Bakris, B. Pitt, Y. Stasiv, 2015 .

Design and Population of the VALOR-CKD Study: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating the Efficacy and Safety of Veverimer in Slowing Progression of Chronic Kidney Disease in Patients with Metabolic Acidosis.

N. Tangri, V. Perkovic, D. Wheeler, 2022, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Effects of veverimer on serum bicarbonate and physical function in diabetic patients with chronic kidney disease and metabolic acidosis: subgroup analysis from a randomized, controlled trial

D. Wesson, E. Li, Vandana S. Mathur, 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.